MG
PVLA

Michael Gelband’s Palvella Therapeutics PVLA Stock Holding History

Michael Gelband’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$840K Sell
5,494
-14,783
-73% -$1.79M 0.01% 1119
2026
Q1 		$2.53M Buy
+20,277
New +$2.12M 0.02% 679
2022
Q2 		– Sell
-607
Closed -$147K – 2548
2022
Q1 		$147K Buy
607
+465
+327% +$122K ﹤0.01% 1962
2021
Q4 		$43K Buy
+142
New +$45.5K ﹤0.01% 2049
2021
Q3 		– Sell
-169
Closed -$52K – 2743
2021
Q2 		$52K Buy
+169
New +$37.1K ﹤0.01% 2219

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Michael Gelband's PVLA Position: Q2 2026 in Review

Michael Gelband reduced its Palvella Therapeutics (PVLA) stake by 73% in Q2 2026, selling an estimated $1.79M and leaving 5,494 shares worth $840K. The position accounts for 0.01% of the portfolio, ranked #1119.

Michael Gelband first reported a position in PVLA in Q2 2021 and has held it in 5 quarters since. The position peaked at $2.53M in Q1 2026. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Michael Gelband held 5,494 shares of Palvella Therapeutics worth $840K as of Q2 2026.
  • Michael Gelband sold 14,783 Palvella Therapeutics shares in Q2 2026, an estimated $1.79M.
  • Palvella Therapeutics made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #1119 holding.
  • Michael Gelband first reported a position in Palvella Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • Michael Gelband's Palvella Therapeutics position peaked at $2.53M in Q1 2026.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.